Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences

LEXINGTON, Mass.--()--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that members of Inotek’s leadership team are scheduled to participate at the following investor conferences in March:

Cowen and Company 37th Annual Health Care Conference

  • Presentation: March 6, 2017 at 4:00pm EST
  • Attendees: David Southwell, President and Chief Executive Officer; Rudolf A. Baumgartner, MD, Executive Vice President, Chief Medical Officer; and Claudine Prowse, PhD, Vice President, Corporate Development and IRO

29th Annual ROTH Conference

  • Presentation: March 13, 2017 at 4:30pm PST
  • Attendee: Claudine Prowse, PhD, Vice President, Corporate Development and IRO

A live audio webcast of the Cowen presentation will be available on the Investors section of the company’s website, www.inotekpharma.com. A replay of the presentation will be archived on the Inotek website following the conference.

About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Inotek Pharmaceuticals
Claudine Prowse, PhD, 781-552-4305
Vice President, Corporate Development and IRO
IR@inotekpharma.com

Release Summary

Inotek Pharmaceuticals announces participation at upcoming investor conferences in March.

Contacts

Inotek Pharmaceuticals
Claudine Prowse, PhD, 781-552-4305
Vice President, Corporate Development and IRO
IR@inotekpharma.com